GTI-2040
information and resources from the National Cancer Institute
NCI Thesaurus | GTI-2040
A 20-mer antisense oligonucleotide complementary to a coding region in the mRNA of the R2 small subunit component of human ribonucleotide reductase. GTI-2040 decreases mRNA and protein levels of R2 in vitro and may inhibit tumor cell proliferation in human tumors in vivo.NCI Thesaurus | GTI-2040
A 20-mer antisense oligonucleotide complementary to a coding region in the mRNA of the R2 small subunit component of human ribonucleotide reductase. GTI-2040 decreases mRNA and protein levels of R2 in vitro and may inhibit tumor cell proliferation in human tumors in vivo.
|
|
|
|
news articles
Lorus announces international conference presentation of the ... Dec 12, 2005
PR Newswire (press release), ...of pharmaceutical products and technologies for the management of cancer, today announced that investigators of the clinical trial of GTI-2040 in acute myeloid ...
Lorus reports positive results in drug trial Dec 13, 2005
Globe and Mail, In a presentation to the American Society of Hematology meeting in Atlanta yesterday, Toronto-based Lorus said its GTI-2040 drug combined with the chemotherapy ...
Lorus announces international conference presentation of the ... Dec 12, 2005
PR Newswire (press release), ...of pharmaceutical products and technologies for the management of cancer, today announced that investigators of the clinical trial of GTI-2040 in acute myeloid ...
Lorus reports positive results in drug trial Dec 13, 2005
Globe and Mail, In a presentation to the American Society of Hematology meeting in Atlanta yesterday, Toronto-based Lorus said its GTI-2040 drug combined with the chemotherapy ...
|
|
